Frank Mottola - Sep 12, 2025 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
SVP, Chief Tech. Ops. Officer
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Stock symbol
SUPN
Transactions as of
Sep 12, 2025
Transactions value $
-$32,350
Form type
4
Date filed
9/15/2025, 05:39 PM
Previous filing
Aug 27, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mottola Frank SVP, Chief Tech. Ops. Officer C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE /s/ Timothy C. Dec, as attorney-in-fact 2025-09-15 0001804567

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $197K +5K +32.27% $39.40 20.5K Sep 12, 2025 Direct
transaction SUPN Common Stock Sale -$229K -5K -24.4% $45.87 15.5K Sep 12, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Employee Stock Option (Right to Buy) Options Exercise $0 -5K -50% $0.00 5K Sep 12, 2025 Common Stock 5K $39.40 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.73 to $45.96. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F2 The option vests in four equal annual installments beginning on February 14, 2019 .